From: Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group
Result
Age (yr)
16.0 ± 7.5
Pubertal status (<Tanner 3:≥ Tanner 3)
9:12
Gender (M:F)
12:9
Ethnicity (White:Black:Hispanic:Other)
11:5:2:3
Ht (cm)
151 ± 24
Wt (kg)
54 ± 25
Up:cr (mg:mg)
9.3 ± 8.8
GFRe (ml/min/1.73 m2)
121 ± 56